Do analysts recommend EXOZ or NRSN?

NeuroSense Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 2,118.74%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe NeuroSense Therapeutics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NeuroSense Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has preferable valuation and earnings, EXOZ or NRSN?

eXoZymes is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio eXoZymes N/A N/A -$9.16M -$1.19 N/A NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A

Is EXOZ or NRSN more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -292.15% -158.66% NeuroSense Therapeutics N/A N/A N/A

Which has preferable valuation and earnings, NRSN or INMB?

INmune Bio is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A INmune Bio N/A N/A -$45.93M -$0.67 N/A

Is NRSN or INMB more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A INmune Bio N/A -82.87% -62.23%

Which has better earnings & valuation, NRSN or IMMP?

NeuroSense Therapeutics has higher earnings, but lower revenue than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A Prima BioMed $6.69M 8.53 -$39.78M N/A N/A

Is NRSN or IMMP more profitable?

Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A Prima BioMed N/A N/A N/A

Which has preferable earnings and valuation, ELTX or NRSN?

Elicio Therapeutics is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elicio Therapeutics N/A N/A -$39.57M -$2.17 N/A NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A

Is ELTX or NRSN more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -1,266.43% -139.94% NeuroSense Therapeutics N/A N/A N/A

Which has higher earnings & valuation, NRSN or INKT?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A MiNK Therapeutics N/A N/A -$12.49M -$2.40 N/A

Is NRSN or INKT more profitable?

Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A MiNK Therapeutics N/A N/A -92.37%

NeuroSense Therapeutics (NRSN) Competitors

$0.38 +0.03 (+9.33%)

As of 03:35 PM Eastern

Compare

NRSN vs. EXOZ, INMB, IMMP, ELTX, and INKT

Should you buy NeuroSense Therapeutics stock or one of its competitors? NeuroSense Therapeutics's main competitors and comparable companies include eXoZymes (EXOZ), INmune Bio (INMB), Prima BioMed (IMMP), Elicio Therapeutics (ELTX), and MiNK Therapeutics (INKT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NeuroSense Therapeutics compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

In the previous week, eXoZymes had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 1 mentions for eXoZymes and 0 mentions for NeuroSense Therapeutics. eXoZymes' average media sentiment score of 0.42 beat NeuroSense Therapeutics' score of 0.00 indicating that eXoZymes is being referred to more favorably in the media.

Company	Overall Sentiment
eXoZymes	Neutral
NeuroSense Therapeutics	Neutral

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 72.4% of eXoZymes shares are owned by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

NeuroSense Therapeutics' return on equity of 0.00% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-292.15%	-158.66%
NeuroSense Therapeutics	N/A	N/A	N/A

NeuroSense Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 2,118.74%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe NeuroSense Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

eXoZymes has a beta of 2.93, indicating that its stock price is 193% more volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market.

eXoZymes is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	N/A	N/A	-$9.16M	-$1.19	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A

Summary

NeuroSense Therapeutics beats eXoZymes on 9 of the 14 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to INmune Bio?

NeuroSense Therapeutics (NASDAQ:NRSN) and INmune Bio (NASDAQ:INMB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

NeuroSense Therapeutics' return on equity of 0.00% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
INmune Bio	N/A	-82.87%	-62.23%

1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by insiders. Comparatively, 21.4% of INmune Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NeuroSense Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 2,118.74%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe NeuroSense Therapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

INmune Bio is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
INmune Bio	N/A	N/A	-$45.93M	-$0.67	N/A

In the previous week, NeuroSense Therapeutics' average media sentiment score of 0.00 equaled INmune Bio'saverage media sentiment score.

Company	Overall Sentiment
NeuroSense Therapeutics	Neutral
INmune Bio	Neutral

NeuroSense Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market. Comparatively, INmune Bio has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Summary

NeuroSense Therapeutics beats INmune Bio on 10 of the 11 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Prima BioMed?

NeuroSense Therapeutics (NASDAQ:NRSN) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

In the previous week, Prima BioMed had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 1 mentions for Prima BioMed and 0 mentions for NeuroSense Therapeutics. Prima BioMed's average media sentiment score of 1.33 beat NeuroSense Therapeutics' score of 0.00 indicating that Prima BioMed is being referred to more favorably in the news media.

Company	Overall Sentiment
NeuroSense Therapeutics	Neutral
Prima BioMed	Positive

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Prima BioMed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

NeuroSense Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 2,118.74%. Prima BioMed has a consensus price target of $5.50, suggesting a potential upside of 1,320.45%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe NeuroSense Therapeutics is more favorable than Prima BioMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Prima BioMed	N/A	N/A	N/A

NeuroSense Therapeutics has higher earnings, but lower revenue than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Prima BioMed	$6.69M	8.53	-$39.78M	N/A	N/A

NeuroSense Therapeutics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.25, suggesting that its stock price is 125% more volatile than the broader market.

Summary

NeuroSense Therapeutics beats Prima BioMed on 6 of the 11 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Elicio Therapeutics?

Elicio Therapeutics (NASDAQ:ELTX) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 50.9% of Elicio Therapeutics shares are held by company insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

NeuroSense Therapeutics' return on equity of 0.00% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-1,266.43%	-139.94%
NeuroSense Therapeutics	N/A	N/A	N/A

Elicio Therapeutics is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A

Elicio Therapeutics currently has a consensus target price of $19.75, indicating a potential upside of 549.67%. NeuroSense Therapeutics has a consensus target price of $8.50, indicating a potential upside of 2,118.74%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe NeuroSense Therapeutics is more favorable than Elicio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Elicio Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market.

In the previous week, Elicio Therapeutics had 14 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 14 mentions for Elicio Therapeutics and 0 mentions for NeuroSense Therapeutics. Elicio Therapeutics' average media sentiment score of 0.63 beat NeuroSense Therapeutics' score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Elicio Therapeutics	Positive
NeuroSense Therapeutics	Neutral

Summary

NeuroSense Therapeutics beats Elicio Therapeutics on 9 of the 14 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to MiNK Therapeutics?

NeuroSense Therapeutics (NASDAQ:NRSN) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by company insiders. Comparatively, 20.4% of MiNK Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MiNK Therapeutics is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A

In the previous week, MiNK Therapeutics had 9 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 9 mentions for MiNK Therapeutics and 0 mentions for NeuroSense Therapeutics. MiNK Therapeutics' average media sentiment score of 0.57 beat NeuroSense Therapeutics' score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
NeuroSense Therapeutics	Neutral
MiNK Therapeutics	Positive

NeuroSense Therapeutics has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

NeuroSense Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 2,118.74%. MiNK Therapeutics has a consensus price target of $35.00, suggesting a potential upside of 190.46%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe NeuroSense Therapeutics is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
MiNK Therapeutics	N/A	N/A	-92.37%

Summary

NeuroSense Therapeutics beats MiNK Therapeutics on 10 of the 13 factors compared between the two stocks.

Get NeuroSense Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRSN vs. The Competition

Export

Metric	NeuroSense Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.47M	$4.01B	$7.30B	$12.80B
Dividend Yield	N/A	3.64%	2.54%	10.69%
P/E Ratio	-0.71	11.66	271.76	24.15
Price / Sales	N/A	1,273.11	596.42	78.67
Price / Cash	N/A	103.92	78.13	53.57
Price / Book	-7.66	17.98	13.45	6.37
Net Income	-$11.12M	-$12.54M	$3.46B	$347.61M
7 Day Performance	-15.45%	2.88%	1.94%	-0.11%
1 Month Performance	-45.27%	6.14%	4.82%	1.95%
1 Year Performance	-66.39%	59.00%	27.35%	20.38%

NeuroSense Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRSN NeuroSense Therapeutics	2.7003 of 5 stars	$0.38 +9.3%	$8.50 +2,118.7%	-70.3%	$14.47M	N/A	N/A	10	Gap Up
EXOZ eXoZymes	0.307 of 5 stars	$6.38 +5.7%	N/A	-28.0%	$58.71M	N/A	N/A	29	News Coverage Gap Up
INMB INmune Bio	0.642 of 5 stars	$2.11 -0.8%	N/A	-8.5%	$58.53M	N/A	N/A	10	Analyst Upgrade Gap Up
IMMP Prima BioMed	3.0587 of 5 stars	$0.40 +2.5%	$5.50 +1,288.9%	-76.4%	$58.36M	$6.69M	N/A	2,021	Positive News Gap Up
ELTX Elicio Therapeutics	3.1227 of 5 stars	$3.05 +1.0%	$19.75 +547.5%	-73.3%	$58.22M	N/A	N/A	N/A	Trending News Analyst Forecast Analyst Revision Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRSN) was last updated on 8/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroSense Therapeutics (NRSN) Competitors

NRSN vs. EXOZ, INMB, IMMP, ELTX, and INKT

How does NeuroSense Therapeutics compare to eXoZymes?

Summary

How does NeuroSense Therapeutics compare to INmune Bio?

Summary

How does NeuroSense Therapeutics compare to Prima BioMed?

Summary

How does NeuroSense Therapeutics compare to Elicio Therapeutics?

Summary

How does NeuroSense Therapeutics compare to MiNK Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN vs. The Competition

NeuroSense Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeuroSense Therapeutics (NRSN) Competitors

NRSN vs. EXOZ, INMB, IMMP, ELTX, and INKT

How does NeuroSense Therapeutics compare to eXoZymes?

Does the media refer more to EXOZ or NRSN?

Do insiders & institutionals hold more shares of EXOZ or NRSN?

Is EXOZ or NRSN more profitable?

Do analysts recommend EXOZ or NRSN?

Which has more volatility and risk, EXOZ or NRSN?

Which has preferable valuation and earnings, EXOZ or NRSN?

Summary

How does NeuroSense Therapeutics compare to INmune Bio?

Is NRSN or INMB more profitable?

Do insiders & institutionals hold more shares of NRSN or INMB?

Do analysts rate NRSN or INMB?

Which has preferable valuation and earnings, NRSN or INMB?

Does the media refer more to NRSN or INMB?

Which has more risk & volatility, NRSN or INMB?

Summary

How does NeuroSense Therapeutics compare to Prima BioMed?

Does the media prefer NRSN or IMMP?

Do institutionals and insiders hold more shares of NRSN or IMMP?

Do analysts rate NRSN or IMMP?

Is NRSN or IMMP more profitable?

Which has better earnings & valuation, NRSN or IMMP?

Which has more risk and volatility, NRSN or IMMP?

Summary

How does NeuroSense Therapeutics compare to Elicio Therapeutics?

Do institutionals & insiders hold more shares of ELTX or NRSN?

Is ELTX or NRSN more profitable?

Which has preferable earnings and valuation, ELTX or NRSN?

Do analysts rate ELTX or NRSN?

Which has more volatility and risk, ELTX or NRSN?

Does the media favor ELTX or NRSN?

Summary

How does NeuroSense Therapeutics compare to MiNK Therapeutics?

Do institutionals and insiders have more ownership in NRSN or INKT?

Which has higher earnings & valuation, NRSN or INKT?

Does the media refer more to NRSN or INKT?

Which has more volatility and risk, NRSN or INKT?

Do analysts prefer NRSN or INKT?

Is NRSN or INKT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN vs. The Competition

NeuroSense Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools